PPP1R3C: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulatory Subunit 3C

Target Name: PPP1R3C

NCBI ID: G5507

PPP1R3C

PPP1R3C: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulatory Subunit 3C

Protein phosphatases are a family of enzymes that regulate various cellular processes, including cell signaling, protein folding, and stability. One of the protein phosphatases that has garnered significant attention in recent years is PPP1R3C, a non-catalytic regulatory subunit of the protein phosphatase 1 (PP1) enzyme. PPP1R3C is primarily expressed in the brain and plays a critical role in regulating the activity of PP1, which is a key enzyme in the protein kinetic network.

Expression and Localization of PPP1R3C

PP1R3C is expressed in various tissues and cells, including the brain, heart, and liver. The highest levels of PPP1R3C are observed in the brain, with lower levels detected in the heart and liver. PPP1R3C is predominantly localized to the endoplasmic reticulum (ER), where it interacts with PP1 and other protein phosphatases.

Function of PPP1R3C

The function of PPP1R3C is well understood in the context of PP1. PPP1R3C is a negative regulator of PP1 and functions by inhibiting the activity of PP1. This inhibition allows PP1R3C to act as a negative feedback mechanism to regulate the activity of PP1 in a physiological manner.

PP1R3C is a key regulatory subunit of PP1 and has been shown to play a critical role in the regulation of various cellular processes, including cell signaling, protein folding, and stability. Studies have demonstrated that PP1R3C interacts with various protein substrates, including casein kinase (2-3), syntaxin (6), and neurotrophin.

Drug Targeting and Biomarker Potential

The potential drug targeting of PPP1R3C is due to its unique function as a negative regulator of PP1. By inhibiting the activity of PP1, PPP1R3C has been shown to play a critical role in the regulation of neurotransmitter release and neuronal communication. Therefore, PPP1R3C may be an attractive drug target for the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

In addition to its potential drug-targeting potential, PPP1R3C also has potential as a biomarker for various neurological disorders. The regulation of PP1 by PPP1R3C is altered in various neurological disorders, including Alzheimer's disease and Parkinson's disease. Therefore, measuring the expression and activity of PPP1R3C may provide valuable information for the diagnosis and treatment of these disorders.

Conclusion

In conclusion, PPP1R3C is a non-catalytic regulatory subunit of the protein phosphatase 1 enzyme that is expressed in various tissues and cells, with highest levels detected in the brain. PPP1R3C plays a critical role in regulating the activity of PP1 and has been shown to interact with various protein substrates. The potential drug targeting of PPP1R3C due to its role in the regulation of neurotransmitter release and neuronal communication makes it an attractive target for the treatment of various neurological and psychiatric disorders. Furthermore, the regulation of PP1 by PPP1R3C is altered in various neurological disorders, making PPP1R3C a valuable biomarker for the diagnosis and treatment of these disorders.

Protein Name: Protein Phosphatase 1 Regulatory Subunit 3C

Functions: Acts as a glycogen-targeting subunit for PP1 and regulates its activity. Activates glycogen synthase, reduces glycogen phosphorylase activity and limits glycogen breakdown. Dramatically increases basal and insulin-stimulated glycogen synthesis upon overexpression in a variety of cell types

The "PPP1R3C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R3C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets